JAZZ · Jazz Pharmaceuticals plc · Webcasts, Transcripts & Audio
$241.55
+1.18 (+0.49%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$15.50B
Shares
64.19M
Volume · Nov 13
496.8K
Avg daily vol (3M)
874.67K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Jazz Pharmaceuticals plc Webcasts
Earnings calls, investor updates, investor days and conferences for Jazz Pharmaceuticals plc (JAZZ), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Conference
Investor event
2026-12-02
Jazz Pharmaceuticals plc (JAZZ) December 2, 2026 Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-12-02
Jazz Pharmaceuticals plc (JAZZ) December 2, 2026 Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-11-17
Jazz Pharmaceuticals plc (JAZZ) November 17, 2026 Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q3
2026-11-02
Jazz Pharmaceuticals plc (JAZZ) Q3 2026 Earnings Call Transcript
Confident tone
Oncology portfolio growth
Actio acquisition and rare epilepsy
Zepzelka competitive outlook
Revenue
$1.24B
▲ 10.4% YoY Diluted EPS
$-7.48
▼ 283.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-10
Jazz Pharmaceuticals plc (JAZZ) September 10, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-09
Jazz Pharmaceuticals plc (JAZZ) September 9, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-03
Jazz Pharmaceuticals plc (JAZZ) Q2 2026 Earnings Call Transcript
Confident tone
Epidiolex Franchise and Capsule Launch
Ziihera/Zanidatamab HER2-positive GEA Launch
Xywav Sleep Franchise
Revenue
$1.21B
▲ 15.5% YoY Diluted EPS
$2.78
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-03
Jazz Pharmaceuticals plc (JAZZ) June 3, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-19
Jazz Pharmaceuticals plc (JAZZ) May 19, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-05
Jazz Pharmaceuticals plc (JAZZ) Q1 2026 Earnings Call Transcript
Confident tone
Quarterly commercial performance
ZYHERA (zanidatumab) GEA launch
Pipeline and R&D progress
Revenue
$1.07B
▲ 19.1% YoY Diluted EPS
$4.43
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-24
Jazz Pharmaceuticals plc (JAZZ) Q4 2025 Earnings Call Transcript
Confident tone
Zanidatamab pipeline and GEA launch
Rare sleep franchise (Xywav/Xyrem)
Epidiolex growth and patent runway
Revenue
$1.20B*
▲ 10.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-05
Jazz Pharmaceuticals plc (JAZZ) Q3 2025 Earnings Call Transcript
Confident tone
Xywav growth and low-sodium positioning
Zanidatamab HERIZON GEA readout
Modeyso launch and Chimerix acquisition
Revenue
$1.13B
▲ 6.7% YoY Diluted EPS
$4.08
▲ 19.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-27
Jazz Pharmaceuticals plc (JAZZ) Q2 2025 Earnings Call Transcript
Positive tone
Financial Guidance
Leadership Transition
Sleep Franchise (Xywav/Xyrem)
Revenue
$1.05B
▲ 2.1% YoY Diluted EPS
$-11.74
▼ 571.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-06
Jazz Pharmaceuticals plc (JAZZ) Q1 2025 Earnings Call Transcript
Confident tone
Zanidatamab pipeline and GEA readout
Dordaviprone and Chimerix acquisition
Xywav and sleep franchise momentum
Revenue
$897.80M
▼ 0.5% YoY Diluted EPS
$-1.52
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-25
Jazz Pharmaceuticals plc (JAZZ) Q4 2024 Earnings Call Transcript
Positive tone
Sleep portfolio (Xywav) navigating oxybate competition
Zanidatamab / HERIZON-GEA-01 readout timing delay
Zepzelca first-line SCLC maintenance expansion
Revenue
$1.09B*
▲ 7.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-06
Jazz Pharmaceuticals plc (JAZZ) Q3 2024 Earnings Call Transcript
Confident tone
Zanidatamab pipeline
Zepzelca and oncology
Xywav commercial performance
Revenue
$1.05B
▲ 8.5% YoY Diluted EPS
$3.42
▲ 59.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-07-31
Jazz Pharmaceuticals plc (JAZZ) Q2 2024 Earnings Call Transcript
Positive tone
Xywav / oxybate franchise
Oncology (Zepzelca, Rylaze, Zanidatamab)
Epidiolex performance and durability
Revenue
$1.02B
▲ 6.9% YoY Diluted EPS
$2.49
▲ 63.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-01
Jazz Pharmaceuticals plc (JAZZ) Q1 2024 Earnings Call Transcript
Confident tone
Xywav / sleep franchise
Oncology portfolio (Zanidatamab, Rylaze, Zepzelca)
Epidiolex growth opportunity
Revenue
$901.98M
▲ 1% YoY Diluted EPS
$-0.23
▼ 122.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-01-08
Jazz Pharmaceuticals plc (JAZZ) Q4 2023 Earnings Call Transcript
Confident tone
Zanidatamab pipeline and peak sales potential
Sleep franchise (Xywav / Xyrem / Lumryz competition)
Oncology portfolio (Rylaze and oncology surpassing $1B)
Revenue
$1.01B*
▲ 4.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-08
Jazz Pharmaceuticals plc (JAZZ) Q3 2023 Earnings Call Transcript
Revenue
$972.14M
▲ 3.3% YoY Diluted EPS
$2.14
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-09
Jazz Pharmaceuticals plc (JAZZ) Q2 2023 Earnings Call Transcript
Revenue
$957.32M
▲ 2.6% YoY Diluted EPS
$1.52
▲ 176.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-10
Jazz Pharmaceuticals plc (JAZZ) Q1 2023 Earnings Call Transcript
Revenue
$892.81M
▲ 9.7% YoY Diluted EPS
$1.04
▲ 3366.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-01
Jazz Pharmaceuticals plc (JAZZ) Q4 2022 Earnings Call Transcript
Revenue
$972.12M*
▲ 8.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-09
Jazz Pharmaceuticals plc (JAZZ) Q3 2022 Earnings Call Transcript
Revenue
$940.65M
▲ 12.2% YoY Diluted EPS
$-0.31
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-03
Jazz Pharmaceuticals plc (JAZZ) Q2 2022 Earnings Call Transcript
Revenue
$932.88M
▲ 24.1% YoY Diluted EPS
$0.55
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
Jazz Pharmaceuticals plc (JAZZ) Q1 2022 Earnings Call Transcript
Revenue
$813.72M
▲ 33.9% YoY Diluted EPS
$0.03
▼ 98.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-01
Jazz Pharmaceuticals plc (JAZZ) Q4 2021 Earnings Call Transcript
Revenue
$896.73M*
▲ 34.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-09
Jazz Pharmaceuticals plc (JAZZ) Q3 2021 Earnings Call Transcript
Revenue
$838.12M
▲ 39.5% YoY Diluted EPS
$-0.86
▼ 132.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-03
Jazz Pharmaceuticals plc (JAZZ) Q2 2021 Earnings Call Transcript
Revenue
$751.81M
▲ 33.7% YoY Diluted EPS
$-6.11
▼ 396.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-04-20
Jazz Pharmaceuticals plc (JAZZ) Q1 2021 Earnings Call Transcript
Revenue
$607.58M
▲ 13.6% YoY Diluted EPS
$2.09
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-23
Jazz Pharmaceuticals plc (JAZZ) Q4 2020 Earnings Call Transcript
Revenue
$665.52M
▲ 14.4% YoY Diluted EPS
$2.33
▲ 80.6% YoY Gross margin
91.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-02
Jazz Pharmaceuticals plc (JAZZ) Q3 2020 Earnings Call Transcript
Revenue
$600.89M
▲ 11.8% YoY Diluted EPS
$2.64
▲ 48.3% YoY Gross margin
92.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-04
Jazz Pharmaceuticals plc (JAZZ) Q2 2020 Earnings Call Transcript
Revenue
$562.44M
▲ 5.3% YoY Diluted EPS
$2.06
▼ 54.8% YoY Gross margin
94.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-05
Jazz Pharmaceuticals plc (JAZZ) Q1 2020 Earnings Call Transcript
Revenue
$534.73M
▲ 5.2% YoY Diluted EPS
$-2.82
▼ 291.8% YoY Gross margin
93.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-01-14
Jazz Pharmaceuticals plc (JAZZ) Q4 2019 Earnings Call
Revenue
$581.74M
▲ 22.1% YoY Diluted EPS
$1.29
▼ 51.1% YoY Gross margin
93.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–35 of 35 webcasts
Key facts
CIK
1232524
CUSIP
G50871105
13F (30d)
536 filings
485 filers
Visit website
Investor relations